Literature DB >> 1903162

Long-term follow-up of brain-damaged children requiring feeding gastrostomy: should an antireflux procedure always be performed?

M J Wheatley1, J R Wesley, D M Tkach, A G Coran.   

Abstract

Due to the frequent presence of latent gastroesophageal reflux (GER) in mentally impaired children, it is now standard to perform upper gastrointestinal contrast (UGI) and pH probe studies in all children referred for feeding gastrostomy, even if they are without clinical evidence for GER. For patients with documented GER, an antireflux operation performed in conjunction with gastrostomy is usually considered mandatory. Some authors have suggested that a "protective" antireflux operation be performed at the time of gastrostomy placement in all brain-damaged children, citing a high incidence of postoperative GER in this group of patients following gastrostomy, even with a negative preoperative evaluation for GER. To evaluate this theory, we prospectively studied, over the past 6 years, all mentally retarded children referred for feeding gastrostomy with UGI contrast and esophageal pH probe studies. In total, 148 children were studied; 105 had a positive evaluation for GER and underwent gastrostomy and antireflux surgery. Of the 43 children with a negative preoperative evaluation for GER, 37 are doing well following gastrostomy alone without clinical reflux at an average follow-up of 21 months. Six of the 43 (14%) developed symptomatic GER occurring at an average of 10 months following gastrostomy placement. Five of these children have been successfully treated with an antireflux operation and the sixth patient has been successfully managed nonoperatively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1903162     DOI: 10.1016/0022-3468(91)90506-o

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

1.  Gastrostomy feeding in the disabled child: when is an antireflux procedure required?

Authors:  P B Sullivan
Journal:  Arch Dis Child       Date:  1999-12       Impact factor: 3.791

2.  Laparoscopic nissen fundoplication with simultaneous percutaneous endoscopic gastrostomy in children.

Authors:  Y Héloury; V Plattner; E Mirallié; P Gérard; C Lejus
Journal:  Surg Endosc       Date:  1996-08       Impact factor: 4.584

3.  Long-term outcome and efficiency of symptom-selective approach to assess gastroesophageal reflux prior to gastrostomy in neurologically impaired children.

Authors:  Hilmican Ulman; Zafer Dokumcu; Vusale Elekberova; Ulgen Celtik; Emre Divarci; Coskun Ozcan; Ata Erdener
Journal:  Pediatr Surg Int       Date:  2021-03-30       Impact factor: 1.827

Review 4.  The relationship between percutaneous endoscopic gastrostomy and gastro-oesophageal reflux disease in children: a systematic review.

Authors:  Louise J Noble; A Mark Dalzell; Wael El-Matary
Journal:  Surg Endosc       Date:  2012-03-22       Impact factor: 4.584

5.  Nissen fundoplication in children with profound neurologic disability. High risks and unmet goals.

Authors:  C D Smith; H B Othersen; N J Gogan; J D Walker
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

6.  Operation for gastro-oesophageal reflux associated with severe mental retardation.

Authors:  L Spitz; K Roth; E M Kiely; R J Brereton; D P Drake; P J Milla
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

Review 7.  Fundoplication versus postoperative medication for gastro-oesophageal reflux in children with neurological impairment undergoing gastrostomy.

Authors:  Angharad Vernon-Roberts; Peter B Sullivan
Journal:  Cochrane Database Syst Rev       Date:  2013-08-28

Review 8.  Gastrostomy feeding in cerebral palsy: a systematic review.

Authors:  G Sleigh; P Brocklehurst
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

9.  To Wrap or Not? Utility of Anti-reflux Procedure in Infants Needing Gastrostomy Tubes.

Authors:  Faraz A Khan; Kelsey Nestor; Asra Hashmi; Saleem Islam
Journal:  Front Pediatr       Date:  2022-03-07       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.